Representative of the Year

Tom Stackhouse, Ph.D., is Associate Director of the Technology Transfer Center at the National Cancer Institute (NCI). The Center serves as the focal point for the implementation of legislation relating to collaborative agreements and inventions for the NCI, including the Frederick National Laboratory of Cancer Research. Dr. Stackhouse oversees the satellite office located in the Frederick National Laboratory of Cancer Research, which provides a full range of technology transfer services to NCI’s scientists located in Frederick. 

Dr. Stackhouse is the NCI’s Alternate laboratory Representative to the FLC. He served on the FLC Executive Board for two terms as a Member-at-Large, as well as on the Recognition, State and Local Government, and Education and Training committees. For the past two years, he has been responsible for advanced training courses at the FLC’s annual meeting. In this capacity he has helped member laboratories and other meeting attendees learn about a variety of topics, including Deemed Export and Export Control, Software Licensing, and the America Invents Act. He has also served as Vice-Chair of the Education and Training Committee, assisting with assembling instructors for basic and intermediate training sessions at the national meeting. 

As a member of the FLC Executive Board, Dr. Stackhouse offered the perspective of a problem-solving professional who could reconcile diverse points of view and propose workable solutions. His many years of experience as a scientist, technology transfer professional, and a seasoned supervisor enable him to approach situations in a multifaceted manner, taking all stakeholders’ interests into account while making decisions. 

Dr. Stackhouse is not only active at the national level, but also at the regional level for the Mid-Atlantic Region (MAR). For the past six years, he has served on the MAR’s Planning Committee, where his contributions have helped shape the annual regional conference and supported many regional initiatives. He and his staff are also active leaders on the Washington, D.C. metro area’s planning team, which is responsible for MAR activities in the area. 

In addition to FLC activities, Dr. Stackhouse shares his expertise through direct interactions with other federal laboratories. He devises strategies and oversees activities that maximize the commercialization of NCI’s inventions to improve public health and provide a return on investment. NCI’s patent portfolio currently has several thousand patents and patent applications, and the licensing of this portfolio by the NIH Office of Technology Transfer generated over $60 million of royalty income in FY11.